Devin Muntz is an associate in the Corporate & Securities Practice Group in the firm’s Chicago office. He advises multinational companies on transactional matters, including mergers and acquisitions, cross-border deals, corporate reorganizations and other strategic transactions.
In his work with clients he brings knowledge in laboratory and clinical trial implementation and management, regulatory oversight and hospital wide quality improvement initiatives garnered from his experience working in two major health systems. Prior to joining the firm he worked for the Anne & Robert H. Lurie Children’s Hospital of Chicago and the Johns Hopkins School of Medicine where he managed clinical and pharmaceutical trials, including protocol implementation, data collection and regulatory control procedures in accordance with FDA, GCP, and IRB guidelines. In his role he performed both clinical and laboratory based research in pediatric hematology, focusing mainly on Sickle Cell Disease and hemophilia.
As an undergraduate at Princeton University, Devin worked in the laboratory of Thomas J. Silhavy, researching membrane biogenesis and signal transduction in Escherichia coli. Specifically, he investigated the manner in which SurA, a chaperone protein in E. coli, is involved in the folding and assembly of outer membrane proteins, culminating in a thesis titled “A SurA independent outer membrane protein, PldA, shows no chaperone specificity for transport and assembly in Escherichia coli”.
Devin’s background in laboratory and clinical research and experience from an internal health care system perspective proves invaluable in his work with clients in licensing, collaboration and corporate matters.
Professional Associations and Memberships
- Chicago Bar Association
- Illinois~United States (2018)
- University of Chicago Law School (JD with Honors) (2018)
- Princeton University (AB Molecular Biology) (2010)
“Feasibility and safety of home exercise training in children with sickle cell anemia”, co-author, Pediatric Blood & Cancer, December 9, 2017
“Self-Reported Physical Activity and Exercise Patterns in Children with Sickle Cell Disease”, co-author, Pediatric Exercise Science, May 22, 2017
“Opioid Prescription Practices at Discharge and 30-Day Returns in Children with Sickle Cell Disease and Pain”, co-author, Pediatric Blood & Cancer, November 1, 2016
“Personalized Reminders Increase Screening for Stroke Risk in Children with Sickle Cell Anemia”, co-author, Southern Medical Journal, September 9, 2016
“Habitual Physical Activity and Exercise Patterns in Children and Adolescents with Sickle Cell Disease” co-author, American Society of Hematology Blood Journal, December 4, 2014
“Heart rate recovery is impaired after maximal exercise testing in children with sickle cell anemia.”, co-author, Journal of Pediatrics, December 2, 2014
2014 American Society of Pediatric Hematology Oncology: “Vitamin D Surveillance and Supplementation in Sickle Cell Disease: A Quality Improvement Project”